Randomised controlled trialcited by the Tayebat archivefull text checked★ key study A-ODD-17 in-depth review

Very aggressive blood sugar lowering in high-risk type 2 diabetes

Effects of intensive glucose lowering in type 2 diabetes.

Overview

Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC et al.. N Engl J Med 2008 · PMID 18539917 · DOI 10.1056/NEJMoa0802743

Pushing HbA1c below 6% increased deaths by about one-fifth and did not reduce heart attacks or strokes significantly.

Does the study support the specific claim? Partly · Methodological quality: high

Original publication

Plain-language summary

Study explained simply

What did the researchers want to find out?: Does targeting a normal HbA1c (<6.0%) reduce cardiovascular events in type 2 diabetes with high cardiovascular risk?
How was the study done?: Multicentre randomised controlled trial (open-label treatment strategies), mean 3.5 years of intensive therapy
How many people, animals or samples were studied?: 10,251; Type 2 diabetes, mean age 62.2, median HbA1c 8.1%, established CVD or additional risk factors
What was actually found?: More deaths (HR 1.22) and more severe hypoglycaemia with intensive therapy; primary CV outcome not significantly reduced.
How large was the observed effect?: HR 1.22 (1.01-1.46) all-cause death; HR 0.90 (0.78-1.04) primary outcome
What do the results mean in everyday life?: Very strict sugar targets are not good for everyone, especially older people with heart disease.
What are the study's limitations?: Strategy trial: cannot attribute harm to a specific drug; Intensive arm stopped early; High-risk population; not generalisable to early diabetes
What does it say about Elawady's specific claim?: Core evidence that near-normal HbA1c targets can harm high-risk type 2 patients (C-INS-04).
Do the results apply to Germany and Europe?: Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.
What can explicitly not be concluded from this study?: That insulin specifically caused the deaths, or that lowering high glucose to moderate targets is harmful.

Scientific in-depth review

1. Full reference

Authors: Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, Probstfield JL, Simons-Morton DG, Friedewald WT
Journal: N Engl J Med
Year: 2008
Identifier: PMID 18539917 DOI 10.1056/NEJMoa0802743 · PMC4551392
Verification: verified – PubMed E-utilities efetch, 2026-10-25
Retracted: no
Corrections: none
Extent checked: full text
Conflicts of interest and funding: NHLBI-funded (grants NHLBI, NINR); individual COI not in abstract.

2. Research question

Does targeting a normal HbA1c (<6.0%) reduce cardiovascular events in type 2 diabetes with high cardiovascular risk?

3. Study design and population

Study design: Randomised controlled trial – Multicentre randomised controlled trial (open-label treatment strategies), mean 3.5 years of intensive therapy
Population: Type 2 diabetes, mean age 62.2, median HbA1c 8.1%, established CVD or additional risk factors
Country: USA and Canada
Period: 2001-2008
Sample size: 10,251
Inclusion and exclusion criteria: HbA1c >=7.5%; age 40-79 with CVD or 55-79 with subclinical disease or >=2 risk factors.

4. Methods and endpoints

Exposure / intervention: Intensive glycaemic therapy targeting HbA1c <6.0% (multiple drugs incl. insulin)
Comparator: Standard therapy targeting HbA1c 7.0-7.9%
Endpoints: Primary: nonfatal MI, nonfatal stroke or CV death; secondary incl. all-cause mortality
Statistical methods: Cox proportional hazards, intention to treat

5. Actual results

Results: HbA1c at 1 year 6.4% vs 7.5%. Primary outcome 352 vs 371 (HR 0.90, 95% CI 0.78-1.04; P=0.16). Deaths 257 vs 203 (HR 1.22, 95% CI 1.01-1.46; P=0.04). Hypoglycaemia requiring assistance and weight gain >10 kg more frequent with intensive therapy (P<0.001). Full text (PMC): CV death HR 1.35 (1.04-1.76).
Absolute risks: Deaths 257/5128 vs 203/5123 (about 5.0% vs 4.0% over the trial; computed from reported counts and full-text group sizes).
Authors' conclusion: Targeting normal HbA1c for 3.5 years increased mortality and did not significantly reduce major cardiovascular events; a previously unrecognised harm of intensive glucose lowering in high-risk type 2 patients.

6. Strengths

Large RCT with hard endpoints
Independent public funding
Adjudicated outcomes

7. Weaknesses

Strategy trial: cannot attribute harm to a specific drug
Intensive arm stopped early
High-risk population; not generalisable to early diabetes

8. Risk of bias

Orienting tool: RoB 2
Type of assessment: simplified assessment (abstract only)
Full formal assessment: no
Overall risk of bias: low
Rationale: Open-label treatment but objective mortality endpoint; randomisation and analysis appropriate.

9. Assessment of the statistical interpretation

Mortality excess is statistically significant but borderline (lower CI 1.01); absolute difference about 1 percentage point. Primary endpoint not significantly reduced.

10. Relevance to the specific claim

Core evidence that near-normal HbA1c targets can harm high-risk type 2 patients (C-INS-04).

11. Independent contrary findings

ADVANCE (I-INS-01) and UKPDS (I-INS-02) show benefits of less extreme intensive control; Bonds (A-INS-14) shows hypoglycaemia did not explain the mortality difference.

12. Transferability to Germany and Europe

Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.

13. Overall methodological judgement

High-quality RCT, correctly quoted by the archive. Supports individualised moderate targets, not avoidance of glucose-lowering therapy.

Multidimensional assessment
Multidimensional assessment
Authenticity of the source	verified
Methodological quality	high
Risk of bias	low
Precision of results	moderate
Directness	direct
Reproducibility	partly replicated
Consistency with the overall evidence	mixed
Regional transferability	high
Adequacy of the interpretation (by the archive)	essentially correct but incomplete

14. Open questions

Mechanism of excess mortality remains unexplained.

15. Linked fact checks

Large trials in type 2 diabetes showed that intensive glucose lowering towards normal HbA1c can be harmful: ACCORD was stopped after intensive therapy raised all-cause mortality by 22%, and severe hypoglycaemia was associated with roughly doubled mortality. – Studies supporting the claim

Use by the Tayebat archive

Note: according to the archive, the studies were compiled by the archive operators. Whether Dr. Elawady himself cited this study is not established.

What the archive says about the study: ACCORD on 10,251 patients: intensive lowering with combined drugs raised total mortality (HR 1.22) and cardiovascular mortality (HR 1.35); trial stopped early; severe hypoglycaemia and weight gain linked.
A. What was actually studied?: Does targeting a normal HbA1c (<6.0%) reduce cardiovascular events in type 2 diabetes with high cardiovascular risk?
B. What did the authors find?: More deaths (HR 1.22) and more severe hypoglycaemia with intensive therapy; primary CV outcome not significantly reduced.
C. What conclusions do the authors themselves draw?: Targeting normal HbA1c for 3.5 years increased mortality and did not significantly reduce major cardiovascular events; a previously unrecognised harm of intensive glucose lowering in high-risk type 2 patients.
D. What does the archive derive from it?: Used as 'the field's own warning that lower the number at any cost is itself a documented harm'.
E. Is this derivation scientifically justified?: Justified for near-normal targets in high-risk patients; CV death HR 1.35 confirmed in full text. Not a justification for rejecting glucose-lowering drugs.
Adequacy of the interpretation (by the archive): essentially correct but incomplete